|
(2R,3S,2'R)-nadolol |
|
CHEBI:60917 |
|
(2R,3S,2'R)-nadolol |
|
An aromatic ether, being the (2R)-3-(tert-butylamino)-2-hydroxypropyl ether of the phenolic hydroxy group of (6R,7S)-5,6,7,8-tetrahydronaphthalene-1,6,7-triol. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
|
Molfile
XML
SDF
|
|
|
|
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12-,14-,15+/m1/s1 |
VWPOSFSPZNDTMJ-YUELXQCFSA-N |
CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
|
|
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drug
A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
antihypertensive agent
Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
|
|
View more via ChEBI Ontology
Outgoing
|
(2R,3S,2'R)-nadolol
(CHEBI:60917)
has role
β-adrenergic antagonist
(CHEBI:35530)
(2R,3S,2'R)-nadolol
(CHEBI:60917)
has role
anti-arrhythmia drug
(CHEBI:38070)
(2R,3S,2'R)-nadolol
(CHEBI:60917)
has role
antihypertensive agent
(CHEBI:35674)
(2R,3S,2'R)-nadolol
(CHEBI:60917)
is a
aromatic ether
(CHEBI:35618)
(2R,3S,2'R)-nadolol
(CHEBI:60917)
is a
secondary amino compound
(CHEBI:50995)
(2R,3S,2'R)-nadolol
(CHEBI:60917)
is a
triol
(CHEBI:27136)
(2R,3S,2'R)-nadolol
(CHEBI:60917)
is enantiomer of
(2S,3R,2'S)-nadolol
(CHEBI:60918)
|
|
Incoming
|
nadolol
(CHEBI:7444)
has part
(2R,3S,2'R)-nadolol
(CHEBI:60917)
(2S,3R,2'S)-nadolol
(CHEBI:60918)
is enantiomer of
(2R,3S,2'R)-nadolol
(CHEBI:60917)
|
(2R,3S)-5-{[(2R)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-1,2,3,4-tetrahydronaphthalene-2,3-diol
|
7518264
|
Reaxys Registry Number
|
Reaxys
|
20945127
|
PubMed citation
|
Europe PMC
|
|
2011-01-10
|
This is the most active diastereoisomer of nadolol, an equimolar mixture of the four possible 2,3-cis-diastereoisomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol. Nadolol is used in the management of cardiac arrhythmias, angina pectoris, and hypertension. It is also used in the prophylactic treatment of migraine, and as an adjunct in the treatment of hyperthyroidism.
|
|